106 related articles for article (PubMed ID: 3595254)
1. Cytotoxic cell function in bronchogenic carcinoma.
Kratikanont P; deShazo RD; Banks DE; Chapman Y
Chest; 1987 Jul; 92(1):90-4. PubMed ID: 3595254
[TBL] [Abstract][Full Text] [Related]
2. In vitro natural killer and lymphokine-activated killer activity in patients with bronchogenic carcinoma.
Dunlap NE; Lane VG; Cloud GA; Tilden AB
Cancer; 1990 Oct; 66(7):1499-504. PubMed ID: 1698527
[TBL] [Abstract][Full Text] [Related]
3. Lymphokine-activated killer cell activity in lung cancer.
LeFever A; Funahashi A
Chest; 1991 Feb; 99(2):292-7. PubMed ID: 1989785
[TBL] [Abstract][Full Text] [Related]
4. Spontaneous lymphokine activated killer (LAK) activity in bronchoalveolar lavage cells from patients with bronchogenic carcinoma.
Stein-Streilein J; Guffee J; Ramos M; Pitchenik AE
Reg Immunol; 1989; 2(6):370-5. PubMed ID: 2485685
[TBL] [Abstract][Full Text] [Related]
5. Phenotype and function of natural killer cells in patients with bronchogenic carcinoma.
LeFever AV; Funahashi A
Cancer Res; 1991 Oct; 51(20):5596-601. PubMed ID: 1655257
[TBL] [Abstract][Full Text] [Related]
6. Production of lymphokine-activated lymphocytes. Lysis of human head and neck squamous cell carcinoma cell lines.
Alessi DM; Hutcherson RW; Mickel RA
Arch Otolaryngol Head Neck Surg; 1989 Jun; 115(6):725-30. PubMed ID: 2785809
[TBL] [Abstract][Full Text] [Related]
7. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE
Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-2-inducible killer activity and its regulation by blood monocytes from autologous lymphocytes of lung cancer patients.
Sone S; Kunishige E; Fawzy F; Yanagawa H; Nii A; Maeda K; Atagi S; Heike Y; Nishioka Y; Mizuno K
Jpn J Cancer Res; 1991 Jun; 82(6):716-23. PubMed ID: 1649813
[TBL] [Abstract][Full Text] [Related]
9. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
Grimm EA; Mazumder A; Zhang HZ; Rosenberg SA
J Exp Med; 1982 Jun; 155(6):1823-41. PubMed ID: 6176669
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic activity of lymphocytes to bronchogenic carcinoma cells in patients with lung cancer.
Yasumoto K; Ohta M; Nomoto K
Gan; 1976 Aug; 67(4):505-11. PubMed ID: 1030675
[TBL] [Abstract][Full Text] [Related]
11. Lung natural killer and interleukin-2 activity in lung cancer. A pulmonary compartment of augmented natural killer activity occurs in patients with bronchogenic carcinoma.
Pitchenik AE; Guffee J; Stein-Streilein J
Am Rev Respir Dis; 1987 Dec; 136(6):1327-32. PubMed ID: 3500659
[TBL] [Abstract][Full Text] [Related]
12. Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.
Grimm EA; Ramsey KM; Mazumder A; Wilson DJ; Djeu JY; Rosenberg SA
J Exp Med; 1983 Mar; 157(3):884-97. PubMed ID: 6601174
[TBL] [Abstract][Full Text] [Related]
13. Augmentation of lymphokine-activated killer cell cytotoxicity by monoclonal antibodies against human small cell lung carcinoma.
Tong AW; Lee JC; Wang RM; Ordonez G; Stone MJ
Cancer Res; 1989 Aug; 49(15):4103-8. PubMed ID: 2545333
[TBL] [Abstract][Full Text] [Related]
14. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
Muralikrishna K; Varalakshmi C; Khar A
Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
[TBL] [Abstract][Full Text] [Related]
15. Lymphokine-activated killer (LAK) cells. I. Differential recovery of LAK, natural killer cells, and cytotoxic T lymphocytes after a sublethal dose of cyclophosphamide.
Ballas ZK
J Immunol; 1986 Oct; 137(7):2380-4. PubMed ID: 3489763
[TBL] [Abstract][Full Text] [Related]
16. Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis.
Phillips JH; Lanier LL
J Exp Med; 1986 Sep; 164(3):814-25. PubMed ID: 3489062
[TBL] [Abstract][Full Text] [Related]
17. Enhanced antimetastatic activity of lymphokine-activated killer cells purified and expanded by their adherence to plastic.
Schwarz RE; Vujanovic NL; Hiserodt JC
Cancer Res; 1989 Mar; 49(6):1441-6. PubMed ID: 2784350
[TBL] [Abstract][Full Text] [Related]
18. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
19. Tumor targets stimulate IL-2 activated killer cells to produce interferon-gamma and tumor necrosis factor.
Chong AS; Scuderi P; Grimes WJ; Hersh EM
J Immunol; 1989 Mar; 142(6):2133-9. PubMed ID: 2493506
[TBL] [Abstract][Full Text] [Related]
20. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells.
Melder RJ; Whiteside TL; Vujanovic NL; Hiserodt JC; Herberman RB
Cancer Res; 1988 Jun; 48(12):3461-9. PubMed ID: 3259468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
